(CD5) Amundi Index Solutions - Ratings and Ratios

Exchange: PA • Country: France • Currency: EUR • Type: Etf • ISIN: LU1681047319

Exchange-Traded Fund, Equity Investment, Large-Cap Stocks

Description: CD5 Amundi Index Solutions

Amundi Index Solutions - Amundi EURO STOXX50 UCITS ETF-D EUR is an exchange-traded fund that aims to replicate the performance of the EURO STOXX50 Index, a benchmark that tracks the 50 largest and most liquid stocks in the Eurozone. By minimizing the tracking error between the funds net asset value and the indexs performance, the fund provides investors with broad exposure to the Eurozones top companies.

The funds investment strategy is centered around tracking the EURO STOXX50 Index, which comprises major European companies such as Nestle, SAP, and TotalEnergies. As a result, the funds performance is closely tied to the overall health of the Eurozone economy and the constituent companies financials. With a strong track record and a large asset base, the fund is well-positioned to provide investors with a diversified portfolio.

Analyzing the funds technical data, we observe that the current price is 84.29 EUR, with a 20-day simple moving average (SMA) of 86.30 EUR and a 50-day SMA of 84.23 EUR. The 200-day SMA stands at 80.98 EUR, indicating a longer-term uptrend. The average true range (ATR) is 0.85 EUR, representing a 1.01% daily volatility. Given the current price action and the SMA configuration, we can infer that the fund is experiencing a short-term correction within a longer-term uptrend.

Combining technical and fundamental analysis, we forecast that the Amundi EURO STOXX50 UCITS ETF-D EUR will continue to track the EURO STOXX50 Index, with potential short-term fluctuations. As the Eurozone economy continues to evolve, the funds performance will be influenced by the constituent companies earnings and the overall market sentiment. With an AUM of 785.80M EUR, the fund is well-established and likely to remain a popular choice among investors seeking Eurozone exposure. Our forecast suggests that the funds price will stabilize around 85 EUR in the short term, with potential for growth towards 90 EUR if the underlying index continues to rise.

Additional Sources for CD5 ETF

Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

CD5 ETF Overview

Market Cap in USD 918m
Category Eurozone Large-Cap Equity
TER 0.09%
IPO / Inception 2018-02-14

CD5 ETF Ratings

Growth Rating 76.2
Fundamental -
Dividend Rating 67.1
Rel. Strength -2.02
Analysts -
Fair Price Momentum 85.63 EUR
Fair Price DCF -

CD5 Dividends

Dividend Yield 12m 2.66%
Yield on Cost 5y 4.66%
Annual Growth 5y 13.65%
Payout Consistency 92.1%
Payout Ratio %

CD5 Growth Ratios

Growth Correlation 3m 46.8%
Growth Correlation 12m 78.7%
Growth Correlation 5y 91.1%
CAGR 5y 12.86%
CAGR/Max DD 5y 0.55
Sharpe Ratio 12m 1.40
Alpha 3.70
Beta 0.592
Volatility 12.46%
Current Volume 3.3k
Average Volume 20d 2.2k
Stop Loss 83.7 (-3.5%)
What is the price of CD5 shares?
As of July 14, 2025, the stock is trading at EUR 86.77 with a total of 3,297 shares traded.
Over the past week, the price has changed by +0.75%, over one month by +1.81%, over three months by +11.33% and over the past year by +10.89%.
Is Amundi Index Solutions a good stock to buy?
Yes. Based on ValueRay's Analyses, Amundi Index Solutions (PA:CD5) is currently (July 2025) a good stock to buy. It has a ValueRay Growth Rating of 76.17 and therefor a clear technical positive rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CD5 is around 85.63 EUR . This means that CD5 is currently overvalued and has a potential downside of -1.31%.
Is CD5 a buy, sell or hold?
Amundi Index Solutions has no consensus analysts rating.
What are the forecasts for CD5 share price target?
According to our own proprietary Forecast Model, CD5 Amundi Index Solutions will be worth about 97 in July 2026. The stock is currently trading at 86.77. This means that the stock has a potential upside of +11.79%.
Issuer Target Up/Down from current
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 97 11.8%